Maximus lowered its fiscal 2026 adjusted EPS forecast to $7.90-$8.20 following the Department of Veterans Affairs' decision to pause performance incentive payments in its medical disability exam program from July 1 to December 31, 2026. The stock currently trades at a lower valuation compared to peers, with risks including shrinking revenue and contract rebidding in 2027. Despite these challenges, Maximus remains a buy with a base case price target of $72.45, reflecting a 9x multiple on EPS guidance.
Maximus and its recent EPS forecast revision provide context for health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Sep 24, 2026 21:45 WIB: Of 100 priced health-sector US stocks tradable on Pluang, 58 rose and 41 fell today. Notable movers include Illumina (ILMN) at USD 268.09 with a 1-day change of +4.98%, BioNano Genomics (BNGO) at USD 1.78 with a 1-day change of +4.71%, and Sana Biotechnology (SANA) at USD 2.94 with a 1-day change of -4.55%.
Analysts have mixed views on VICI Properties, a REIT focused on gaming and hospitality properties, with some lowering price targets due to refinancing costs and rent growth limits. Despite these concerns, the company maintains strong fundamentals inc...
Roth Capital upgraded Okta's price target from $155 to $235 and maintained a Buy rating following the company's new AI agent identity strategy unveiled at its Investor Summit. Okta aims to expand beyond traditional identity management by securing AI ...
Vecima Networks reported strong quarterly results with revenue of $64.04 million, surpassing the $55.69 million estimate, and earnings per share of $0.15, beating the $0.14 forecast. The company, a broadband technology provider for cable and fiber op...
Bank of America raised its price target for Okta Inc to $220 from $200 following the company's announcement of new AI-agent security and identity features at the Oktane 2026 conference. These enhancements include Agent SSO, runtime enforcement, and s...
Jefferies reaffirmed its $110 price target on Uber Technologies, highlighting the company's expanding Mobility product suite as a key driver for faster bookings growth and margin expansion. The broker expects Uber's adjusted EBITDA to grow over 25% t...
